Search
Adrafinil
go.drugbank.com/drugs/DB08925ApprovedWithdrawnIt was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission. … Adrafinil is metabolized to [modafinil].
Morphine
go.drugbank.com/drugs/DB00295ApprovedInvestigationalMorphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: (7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diolAdemetionine
go.drugbank.com/drugs/DB00118ApprovedInvestigationalNutraceuticalPhysiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Synonyms: SAM-eCerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]
Belimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigational[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.
Adalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigational[A39983] Several biosimilars to adalimumab. Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018. … A high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), a biosimilar to Humira®, was approved by the FDA in May 2024 for the treatment of multiple chronic inflammatory diseases.
Products: HUMIRA TM, HUMIRA 40MG ILO I E FERPropanoic acid
go.drugbank.com/drugs/DB03766ApprovedInvestigationalVet approvedWithdrawnIts use as a food additive is also approved in Europe. Sodium propionate is is prepared by neutralizing propionic acid with sodium hydroxide. … Sodium propionate was previously approved in Canada as an active ingredient in Amino-Cerv (used to treat inflammation or injury of the cervix).
Sepetaprost
go.drugbank.com/drugs/DB12043InvestigationalSepetaprost has been used in trials studying the treatment of Open Angle-glaucoma, Ocular Hypertension, and Mild Open Angle-glaucoma (OAG).
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalIt is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigationalDesogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. … [F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].
Mixtures: DESOGESTREL E ETINILESTRADIOLO ARISTO, DESOGESTREL E ETINILESTRADIOLO ARISTOCategories: Sex Hormones and Modulators of the Genital System